deoxyglucose has been researched along with Cytokine Release Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hida, S; Kajita, M; Naito, Z; Onda, M; Taki, S; Tanaka, N; Tanimura, A; Uehara, I | 1 |
| Adhikary, A; Dwarakanath, BS; Papineni, RVL; Verma, A; Woloschak, G | 1 |
2 other study(ies) available for deoxyglucose and Cytokine Release Syndrome
| Article | Year |
|---|---|
2-Deoxy-d-glucose induces deglycosylation of proinflammatory cytokine receptors and strongly reduces immunological responses in mouse models of inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Cytokine Receptor gp130; Cytokine Release Syndrome; Cytokines; Deoxyglucose; Glycosylation; Inflammation; Janus Kinases; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, Cytokine; Receptors, Interleukin-6 | 2022 |
A combinatorial approach of a polypharmacological adjuvant 2-deoxy-D-glucose with low dose radiation therapy to quell the cytokine storm in COVID-19 management.
Topics: Betacoronavirus; Combined Modality Therapy; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Deoxyglucose; Humans; Pandemics; Pneumonia, Viral; Radiotherapy Dosage; SARS-CoV-2 | 2020 |